Jaguar health submits abstract for first-of-kind study evaluating the impact of diarrhea from cancer therapies in breast cancer patients who received placebo in its ontarget phase 3 trial

San francisco, ca / accesswire / october 8, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the ontarget phase 3 study recently conducted by jaguar family company napo pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. in this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy.
JAGX Ratings Summary
JAGX Quant Ranking